Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Conditional restriction
2026 S3: prohibited at all times; Specified. A conditional inhaled exception applies; all limits and qualifications below matter. [1]
S3; printed p. 9 and relevant S5 note, p. 12 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and formulations
The US Breo Ellipta label combines vilanterol, a long-acting beta-2 agonist, with the inhaled corticosteroid fluticasone furoate for maintenance treatment of COPD or specified asthma populations. It is not an acute rescue medicine. [2]
- Product and jurisdiction specific; this is not an exhaustive brand, indication or route inventory.
Selected health warnings
Warnings include duplicate-LABA exposure, paradoxical bronchospasm and cardiovascular effects. Additional risks such as oral candidiasis and pneumonia in COPD concern the combination product and should not be assigned indiscriminately to vilanterol alone. [2]
- No treatment dose, device conversion or personal eligibility determination is provided.
Limits of the inhaled exception
The 2026 List gives inhaled vilanterol an exception capped at 25 micrograms over 24 hours. [1]
- These are anti-doping limits, not recommended or safe medical doses. Other routes, products, combined exposure and TUE requirements need individual review.
What remains uncertain
- No exact ordinary-food or supplement-contamination pathway was established by the retained sources; this is a research limitation, not proof of absence.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- Breo Ellipta fluticasone furoate and vilanterol US label ↗Accessed 2026-11-10 · Current label highlights and selected full-text sections
Indications and Usage; formulation; Warnings and Precautions; selected interactions/clinical pharmacology
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.